Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Investigation of the Effectiveness of Short Wave Diathermy Treatment in Patients With Hand Osteoarthritis

NCT06739096 · tracked via the Priya Life Science Turkey tracker
Sponsor
Omer Sezgin
Phase
Not applicable
Started
2024-03-18
Last updated
2025-11-26

Condition(s) studied

Hand OsteoarthritisOsteoarthritis

Investigational drug(s) / intervention(s)

Short Wave DiathermyExerciseSham Short Wave Diathermy

Short Wave Diathermy: Shortwave diathermy (SWT) is a form of electromagnetic therapy that causes the movement of ions, the disruption of molecules, and the generation of eddy currents, which ultimately produce heat in deep tissue. Its claimed mechanism of action includes inducing an anti-inflammatory response, reducing joint stiffness, stimulating connective tissue repair, and reducing muscle spasm and pain.

Exercise: range of motion, strengthening and stretching exercises

Sham Short Wave Diathermy: Sham protocol

Study summary

The aim of this randomized, double-blind, placebo-controlled study was to evaluate the effects of shortwave diathermy therapy on pain, grip strength, and functionality in patients with hand osteoarthritis.

Eligibility

Sex
ALL
Min age
35 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * To be between 35-75 years old * Diagnosis of hand osteoarthritis according to the ACR 1990 Criteria Exclusion Criteria: * Chronic inflammatory diseases (rheumatoid arthritis, seronegative spondyloarthropathy, gout, hemochramatosis, etc.) * Malignancy * Having uncontrolled systemic disease (cardiovascular, pulmonary, hematologic, hepatic, renal, endocrinologic) * Synovitis, tenosynovitis, entrapment neuropathy, contracture, open wound in hand/wrist * History of hand fracture and/or operation * Regular use of nonsteroidal anti-inflammatory drugs in the last three weeks * Regular use of diaserin, chondroitin sulfate, glucosamine in the last three months * Body Mass Index greater than 35

Primary outcome measure(s)

  • Visual Analog Scale — At the beginning of treatment (week 0), at the end of treatment (week 3) and 12 weeks after the end of treatment (week 15)
    0-10 scale. Higher scores represent more severe pain.
  • hand dynamometer and pinchmeter measurements — At the beginning of treatment (week 0), at the end of treatment (week 3) and 12 weeks after the end of treatment (week 15)
    Measurements will be made three times for each fine force on both hands and the average values will be recorded in kg.

Trial sites (1)

FacilityCityRegionStatus
Haydarpaşa Numune Training and Research Hospital Istanbul Istanbul
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06739096 on ClinicalTrials.gov ↗ ← All trials in Turkey